Jim Robinson was appointed Chief Executive Officer of Urovant on March 23, 2020, having served as a member of our board of directors since March 2019. Mr. Robinson is a proven leader in the biopharmaceutical and healthcare industries having successfully led multiple global businesses, operations and commercial ventures in multiple corporations over the past 28 years. Most recently, Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences where he oversaw Paragon’s operations. Previously, Mr. Robinson served as the President and Chief Operating Officer of Alkermes, where he was responsible for global commercial, new product planning, corporate planning, manufacturing, quality, human resources and business development functions. Prior to Alkermes, Mr. Robinson spent over twelve years at Astellas U.S. – most recently as President, Americas Operations where his responsibilities included all aspects of operations for North and South America. Prior to that, he was President of Astellas Pharma US, where he was responsible for leading the U.S. commercial organization. Prior to Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals where his last role was Vice President, Hepatitis Sales and Managed Care. Mr. Robinson serves on the Board of Directors for Neos Therapeutics and the Chicago Botanic Garden and is a founding member of MATTER. Previously, Mr. Robinson served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and served as Chairman of PhRMA’s State Committee. Mr. Robinson received a Bachelor of Science degree from DePaul University.
Cornelia Haag-Molkenteller, M.D., Ph.D. has served as the Chief Medical Officer of USI since April 2018. From April 2015 to March 2018, Dr. Haag-Molkenteller was the Vice President in Clinical Development at Allergan plc (previously Allergan Inc.), and from November 2007 to March 2015, the Vice President in Global Drug Development. While at Allergan, she led clinical development of onabotulinumtoxinA (BOTOX) for OAB and neurogenic detrusor overactivity. From 1988 to 2006, she was the Vice President of Clinical Program Leadership at Schwarz Biosciences GmbH. Dr. Haag-Molkenteller earned an M.D. and Ph.D. from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Walt Johnston was appointed Senior Vice President, Commercial, of Urovant Sciences in June 2020. In this role, Walt is responsible for marketing, sales, and commercial operations. Mr. Johnston is a 30-year veteran in the pharmaceutical industry, specializing in U.S. and global sales and marketing strategies with extensive experience delivering significant revenue growth. Prior to joining Urovant, Mr. Johnston spent 12 years at Astellas Pharma, most recently as Senior Vice President, Urology and Hospital Business Unit. Prior to this role, Mr. Johnston served as Vice President, Marketing and New Product Planning. Prior to Astellas, Mr. Johnston spent 18 years at Pfizer, where his roles included leading the cardiovascular marketing portfolio and National Sales Director, Vista Rx team. Previously, Mr. Johnston served on the board of the Illinois Biotechnology Industry Organization (iBIO), including as Chair of the Board from 2018 to 2019. Mr. Johnston earned a Bachelor of Arts degree from Lafayette College and an MBA from Boston College, Carroll School of Management.
Mr. Bansal brings over 16 years of finance, business development, accounting and mergers and acquisitions experience as a Chief Financial Officer for several leading and innovative biotechnology companies such as Onconova Therapeutics, Inc., Complete Genomics, Lexicon Pharmaceuticals, Inc., Tercica, Inc., Nektar Therapeutics and most recently with ViewRay, Inc. From June 2016 to September 2019, Mr. Bansal served as Chief Financial Officer of ViewRay, Inc., a designer and manufacturer of the MRIdian® radiation therapy system. From March 2013 to February 2016, he served as Chief Financial Officer of Onconova Therapeutics, a phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Prior to his leadership roles as Chief Financial Officer, Mr. Bansal spent over 15 years as a management consultant with firms such as McKinsey & Company, and ZS Associates, Inc., and in various management positions at Novartis, a pharmaceutical company and at Mehta Partners, a financial advisory firm. Mr. Bansal received a B.S. in Mechanical Engineering from the Indian Institute of Technology (Delhi) and an M.S. in Operations Research and an M.B.A. from Northwestern University.
Christine G. Ocampo has served as our Principal Financial and Accounting Officer since May 2018, and as the Senior Vice President and Chief Accounting Officer of USI since October 2017. From September 2015 to May 2017, Ms. Ocampo was the Senior Vice President and Chief Financial Officer of Otic Pharma, Ltd., until it was acquired by Novus Therapeutics, after which she served as the Chief Financial and Compliance Officer until July 2017, and as a consultant from July 2017 to October 2017. Ms. Ocampo has over 20 years of accounting and finance experience, including over 11 years as the head of Finance for publicly traded companies in the healthcare industry. From 2007 to September 2015, Ms. Ocampo served in various roles at Avanir, including Vice President of Finance, Chief Accounting Officer and Vice President of Finance, Chief Compliance Officer and Secretary. From 2001 to 2006, Ms. Ocampo served as the Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer, Secretary and Vice President, Corporate Controller of Cardiogenesis Corporation (now CryoLife, Inc.), a publicly traded medical device company. From 1996 to 1997, Ms. Ocampo held a management role in Finance at Mills-Peninsula Health Systems in Burlingame, California, and from 1994 to 1996, served as an auditor for Ernst & Young LLP. Ms. Ocampo earned a B.A. in Accounting from Seattle University and is a licensed Certified Public Accountant in the state of Washington.
Bryan E. Smith has served as the General Counsel of Urovant Sciences since April 2018. Mr. Smith most recently served as Associate Vice President and Senior Counsel at Allergan, where he was chief counsel to the company’s Urology, Neurology, Aesthetics, and Dermatology business units. Mr. Smith also led Allergan’s anti-counterfeiting and anti-diversion efforts in close cooperation with the U.S. Food & Drug Administration’s Office of Criminal Investigations and other federal, state, and international law enforcement agencies. Prior to joining Allergan, Mr. Smith was a litigator at Gibson, Dunn & Crutcher LLP. Mr. Smith received his B.A. in Political Science from Brigham Young University and his J.D. from the University of Southern California Law School. After graduating from law school, Mr. Smith was a law clerk to the Honorable Cormac J. Carney in the United States District Court for the Central District of California.
Nori Ebersole has served as the Senior Vice President and Chief Human Resources Officer of USI since December 2017. From September 2015 to December 2017, Ms. Ebersole was the Chief Human Resources Officer and Chief Talent Officer at Paul Hastings LLP. From April 1997 to June 2015, Ms. Ebersole served in various roles at Allergan, including most recently as Vice President, Human Resources from January 2014 to June 2015, partnering with executives globally on key strategic initiatives in the Urology, Neurology, Dermatology, Ophthalmology and Aesthetics business units. At Allergan, Ms. Ebersole led numerous commercial and R&D expansions, compensation planning, leadership development and retention strategies. Ms. Ebersole earned a B.S. in Business Administration from the University of Southern California Marshall School of Business.
David N. Hovland, Ph.D., has served as the Senior Vice President Global Regulatory Affairs since March 2018. Dr. Hovland has over 18 years of experience in R&D in the pharmaceutical industry and has contributed to the global development and registration of multiple small molecule and biotechnology-derived pharmaceutical products. From 2015 to 2018, he served as Vice President, Global Regulatory Affairs at Allergan where he was the Global Regulatory Affairs Therapeutic Area Head for Neurology, Urology and Dermatology. Prior to that he served as Head of the Global Regulatory Operations function at Allergan, as a Senior Director from 2010 to 2013 and as a Vice President from 2013 to 2015. From 2006 to 2010, Dr. Hovland was a Director in the Global Regulatory Affairs and Safety department at Amgen, where he served as a global regulatory strategy leader on pharmaceutical development teams. Dr. Hovland started his career in the pharmaceutical industry in nonclinical development as a study director and project team toxicologist, first at Allergan from 1999 to 2002 and subsequently at Amgen from 2002 to 2006. Dr. Hovland earned his Ph.D. in Environmental Health Sciences from the School of Public Health at the University of California, Los Angeles, and his B.S. in Bioresource Sciences from the College of Natural Resources at the University of California, Berkeley.
Kenton Stewart was appointed as Senior Vice President, Market Access of Urovant Sciences in June 2020. In this role, he is responsible for all aspects of market access, including account management, market access marketing, reimbursement strategy, contracts and pricing, and market access alliance management. As a seasoned pharmaceutical executive with nearly 30 years’ experience at several leading global pharmaceutical companies, Mr. Stewart has extensive experience building commercial capabilities and leading successful product launches across multiple therapeutic franchises. Prior to joining Urovant, Mr. Stewart led the development and launch of the Health Systems Business Unit at Alkermes. Prior to Alkermes, Mr. Stewart served in various leadership roles at Astellas Pharma from 2006 to 2018, most recently serving as Senior Vice President of Health Systems. Earlier in his career, Mr. Stewart led licensing and business development at TAP Pharmaceutical Products, with responsibilities for corporate business development, external commercial collaborations, and acquisitions. Previously, he served in various roles at Abbott Laboratories, including sales, sales management, product management and marketing management. Mr. Stewart earned a Bachelor’s degree in Business Administration, Marketing, from Wichita State University. He holds a Master of Business Administration from Bellevue University.